摘要
目的:探讨miR-133a在急性髓系细胞白血病(AML)骨髓有核细胞中的表达及意义。方法:收集37例AML初诊患者及25例化疗后完全缓解患者、12例急性淋巴细胞白血病(ALL)初诊患者和22例骨髓象正常的发热患者的骨髓标本。分离有核细胞,抽提总RNA,以U6为内参,采用实时荧光定量茎环RT-PCR检测并比较AML、ALL及骨髓象正常的非白血病患者骨髓有核细胞中miR-133a的表达,同时比较miR-133a在AML常见亚型及化疗缓解前后的表达水平。结果:miR-133a在AML初诊患者骨髓中相对表达量(N=2-△Ct)明显高于ALL和非白血病患者(P<0.05);M3、M4及M5三种常见AML类型中,M5患者的骨髓标本miR-133a表达明显高于M3患者(P<0.05);AML化疗完全缓解后骨髓有核细胞中miR-133a的表达较化疗前明显下降(P<0.05)。结论:miR-133a可能参与AML的发生发展进程,其骨髓表达水平可为化疗敏感性评价提供一个新的指标。
Objective： To probe the expression and clinical significance of miR-133a in the marrow of acute myeloid leukemia （AML）. Methods： Marrow tissues from 37 AML patients before chemotherapy, 25 AML patients with complete remission （CR） after chemotherapy, 12 acute lymphoblastic leukemia （ALL） patients before chemotherapy and 22 non-leukemia （NL） fever patients with normal bone marrow picture were collected. Total RNA from nucleated cells of these samples were extracted and analyzed for miR-133a expression by stem-loop RT real-time- PCR based on the SYBR Green I. The differences in M3, M4 and M5 patients and the change of miR-133a expression in before-and after-chemotherapy AML patients were further analyzed. Results： Expression levels of miR-133a were slgnificantly higher in marrow tissues of AML patients before chemotherapy than that in those of ali patients before chemotherapy and non- leukemia patients （P〈 0.05）. The expression of miR-133a in the marrow tissues of MS-type patients was significantly higher than that in M3-type AML （P〈 0.05）. Compared to before- chemotherapy patients, the expression levels of miR-133a in the AML patients with complete remission （CR） after chemotherapy decreased significantly （P〈 0.05）. Conclusion： MiR-133a may play an important role in the development and progression of AML and the level of miR-133a expression may be a potential biomarker for the sensitivity of AML treatment.
出处
《温州医学院学报》
CAS
2012年第6期517-520,525,共5页
Journal of Wenzhou Medical College
基金
浙江省教育厅科研基金资助项目(Y200907403)
温州市科技局科研基金资助项目(Y20090103)
